SQZ Biotechnologies Company (SQZB)
OTCMKTS · Delayed Price · Currency is USD
0.0240
+0.0001 (0.42%)
Apr 7, 2026, 10:52 AM EST
SQZB Revenue
SQZ Biotechnologies Company had revenue of $12.12M in the twelve months ending September 30, 2023, down -44.62% year-over-year. In the year 2022, SQZ Biotechnologies Company had annual revenue of $21.48M, down -20.74%.
Revenue (ttm)
12.12M
Revenue Growth
-44.62%
P/S Ratio
0.06
Revenue / Employee
228.70K
Employees
53
Market Cap
707.79K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 21.48M | -5.62M | -20.74% |
| Dec 31, 2021 | 27.10M | 6.10M | 29.05% |
| Dec 31, 2020 | 21.00M | 889.00K | 4.42% |
| Dec 31, 2019 | 20.11M | 7.44M | 58.73% |
| Dec 31, 2018 | 12.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Emmaus Life Sciences | 12.45M |
| EV Biologics | 9.47M |
| Lyra Therapeutics | 398.00K |
| Eastgate Biotech | 137.64K |
| THC Farmaceuticals | 18.52K |
| Halberd | 6.94K |
SQZ Biotechnologies Company News
- 2 years ago - STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company - Business Wire
- 2 years ago - Asset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders - Business Wire
- 2 years ago - SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates - Business Wire
- 2 years ago - SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting - Business Wire
- 2 years ago - SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates - Business Wire
- 2 years ago - SQZ Biotechnologies Provides Update on Collaboration with Roche - Business Wire